12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-22), Forty Seven's 12-1 Month Momentum % is 441.31%.
The industry rank for Forty Seven's 12-1 Month Momentum % or its related term are showing as below:
FTSV's 12-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -26.745
vs FTSV: 441.31
Competitive Comparison of Forty Seven's 12-1 Month Momentum %
For the Biotechnology subindustry, Forty Seven's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forty Seven's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Forty Seven's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Forty Seven's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Forty Seven 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Forty Seven's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FTSV has been successfully added to your